Effect of hypertriglyceridemia on endotoxin responsiveness in humans.
Triglyceride-rich lipoproteins can inhibit endotoxin activity in vitro and in rodents. We sought to determine whether Intralipid, a triglyceride-rich fat emulsion which in contact with plasma functions similarly to endogenous lipoproteins, can alter the human response to endotoxin. Intralipid inhibited endotoxin-induced cytokine production in human whole blood in vitro in a dose-dependent manner, with maximal inhibition (up to 70%) being achieved at a concentration of 10 g/liter. In healthy men, a bolus intravenous injection of endotoxin (lot EC-5; 20 U/kg of body weight) was given midway through a 4-h infusion (125 ml/h) of either 5% glucose (n = 5) or 20% Intralipid (n = 5). The infusion of Intralipid led to an increase in triglyceride levels in serum from 95 +/- 16 to 818 +/- 135 mg/dl prior to endotoxin administration, i.e., levels that importantly reduced cytokine production in endotoxin-stimulated whole blood. However, in vivo hypertriglyceridemia did not influence inflammatory responses to endotoxin (fever, release of tumor necrosis factor and soluble tumor necrosis factor receptors, and leukocytosis) or even potentiated endotoxin responses (release of interleukins 6 and 8 and neutrophil degranulation). Hypertriglyceridemia does not inhibit the in vivo responses to endotoxin in humans.
van der Poll
T
T
Laboratory of Surgical Metabolism, Cornell University Medical College, New York, New York 10021, USA.
Braxton
C C
CC
Coyle
S M
SM
Boermeester
M A
MA
Wang
J C
JC
Jansen
P M
PM
Montegut
W J
WJ
Calvano
S E
SE
Hack
C E
CE
Lowry
S F
SF
D000328:Adult; D016207:Cytokines / Q000096:biosynthesis; D005217:Fat Emulsions, Intravenous / Q000494:pharmacology; D006801:Humans; D015228:Hypertriglyceridemia / Q000276:immunology*; D007958:Leukocyte Count; D008070:Lipopolysaccharides / Q000633:toxicity*; D008297:Male
D016207:Cytokines; D005217:Fat Emulsions, Intravenous; D008070:Lipopolysaccharides